Biocon Q4 Net Profit Soars 154% YoY to ₹344.5 Crore

11 May 2025 , 08:59 AM

Biocon Ltd. released its Q4 FY 25 results.  The pharma major posted consolidated net profit of ₹344.5 crore in Q4FY25, down from ₹135.5 crore in the corresponding quarter last year.

The company’s net profit rose 162%, reflecting continued operational efficiency and enhancement of core business areas. Revenue during the quarter was ₹4,417 crore, an increase of 12.8% over year ago levels.

The operating performance was also good as EBITDA increased 17.7% to ₹1,078.2 crore in March quarter compared with ₹915.9 crore in Q4 FY24. The firm’s EBITDA margin grew to 24.4% in Q4FY25 from 23.4% in the prior year corresponding quarter. This also exceeded the guided 22.6% margin.

Better margins and profitability are a demonstration of better cost control as well as an improved business mix, i.e., its generics and biosimilars businesses. Along with the earnings, the board of Biocon has placed before them the proposal for paying a final dividend of ₹0.50 per equity share, or 10% of the face value of ₹5 per share.

The date of July 4, 2025, shall be used for payment of the final dividend. Payment of the dividend shall be made on or before September 5, 2025, pending approval by the shareholders.